


Edited by János Fischer and David P. Rotella

Successful Drug Discovery




IUPAC

INTERNATIONAL UNION OF
PURE AND APPLIED CHEMISTRY

Edited by János Fischer and David P. Rotella

Successful Drug Discovery



WILEY-VCH
Verlag GmbH & Co. KGaA

The Editors

János Fischer

Gedeon Richter Plc.
Department of Medicinal Chemistry
Gyömrői út 30
1103 Budapest
Hungary

David P. Rotella

Montclair State University
Department of Chemistry & Biochemistry
1, Normal Ave, Montclair
New Jersey 07043
United States

■ All books published by **Wiley-VCH** are carefully produced. Nevertheless, authors, editors, and publisher do not warrant the information contained in these books, including this book, to be free of errors. Readers are advised to keep in mind that statements, data, illustrations, procedural details or other items may inadvertently be inaccurate.

Library of Congress Card No.: applied for

British Library Cataloguing-in-Publication Data

A catalogue record for this book is available from the British Library.

Bibliographic information published by the Deutsche Nationalbibliothek

The Deutsche Nationalbibliothek lists this publication in the Deutsche Nationalbibliografie; detailed bibliographic data are available on the Internet at <http://dnb.d-nb.de>.

© 2015 Wiley-VCH Verlag GmbH & Co. KGaA, Boschstr. 12, 69469 Weinheim, Germany

All rights reserved (including those of translation into other languages). No part of this book may be reproduced in any form – by photoprinting, microfilm, or any other means – nor transmitted or translated into a machine language without written permission from the publishers. Registered names, trademarks, etc. used in this book, even when not specifically marked as such, are not to be considered unprotected by law.

Print ISBN: 978-3-527-33685-2

ePDF ISBN: 978-3-527-67844-0

ePub ISBN: 978-3-527-67845-7

Mobi ISBN: 978-3-527-67846-4

oBook ISBN: 978-3-527-67843-3

Typesetting Laserwords Private Limited, Chennai, India

Printing and Binding Markono Print Media Pte Ltd., Singapore

Printed on acid-free paper

Edited by
János Fischer and David P. Rotella

Successful Drug Discovery

Related Titles

Li, J., Corey, E.J. (eds.)

Drug Discovery

Practices, Processes, and Perspectives

2013

Print ISBN: 978-0-470-94235-2, also available
in digital formats

Huang, X., Aslanian, R.G. (eds.)

Case Studies in Modern Drug Discovery and Development

2012

Print ISBN: 978-0-470-60181-5, also available
in digital formats

Fischer, J., Ganellin, C.R., Rotella, D.P. (eds.)

Analogue-based Drug Discovery III

2012

Print ISBN: 978-3-527-33073-7, also available
in digital formats

Ravina, E.

The Evolution of Drug Discovery

**From Traditional Medicines to Modern
Drugs**

2011

Print ISBN: 978-3-527-32669-3

Fischer, J., Ganellin, C.R. (eds.)

Analogue-based Drug Discovery II

2010

Print ISBN: 978-3-527-32549-8, also available
in digital formats

Advisory Board Members

Klaus P. Bøgesø

(Lundbeck, Denmark)

Kazumi Kondo

(Otsuka, Japan)

John A. Lowe III

(JL3Pharma LLC)

Barry V.L. Potter

(University of Bath, UK)

Preface

The International Union of Pure and Applied Chemistry (IUPAC) has supported this new book project; the book has key inventors describe their new drug discoveries and aims to study the general aspects of successful drug discoveries and the optimization in a drug class.

The book *Successful Drug Discovery* is a continuation of the three volumes of *Analogue-based Drug Discovery* where analogs of existing drugs were the focus. The new book has a broader scope because it includes both pioneer drugs and their analogs and spans all the important types of small-molecule-, peptide-, and protein-based drugs.

The editors thank the advisory board members: Klaus P. Bøgesø (Lundbeck, Denmark), Kazumi Kondo (Otsuka, Japan), John A. Lowe III (JL3Pharma LLC, USA), and Barry VL Potter (University of Bath, UK). Special thanks are due to the following reviewers who helped both the authors and the editors: Klaus Bøgesø, Derek Buckle, Matthias Eckhardt, Arun Ganesan, William Greenlee, Katalin Hornok, Roy Jefferis, Béla Kiss, Patrizio Mattei, Eckhard Ottow, John Proudfoot, Joerg Senn-Bilfinger, István Tarnawa.

The first volume of *Successful Drug Discovery* consists of three parts.

Part I: (General Aspects)

Serendipity is an important part of drug discovery that can be present at each step. The first chapter – written by the editors of this book – reveals special serendipitous cases of some important drug discoveries where the key lead molecule and the drug have been discovered on different targets.

David C. Swinney analyzed the molecular mechanism of action in drug discovery. Phenotypic and target-based drug discovery approaches are discussed from the viewpoint of pioneer drugs and analogs.

Part II: (Drug Class)

John M. Beals gives an overview of insulin analogs, which optimize PK/PD profiles but also provide sufficient stability for the treatment of type 1 and type 2 diabetes mellitus. Rapid-acting and long-acting analogs are summarized.

Part III: (Case Histories)

- 1) *Avanafil*
Kiichiro Yamada, Tosiaki Sakamoto, Kenji Omori, and Kohei Kikkawa described the discovery of the new and highly selective PDE5 inhibitor with rapid onset of action. The researchers succeeded in a remarkably short period to create a structurally new drug.
- 2) *Dapagliflozin*
William N. Washburn reports on the discovery of dapagliflozin which was the first SGLT2 inhibitor approved for the treatment of type 2 of diabetes. A C-glucoside side product that was characterized during early SAR studies serendipitously became the lead structure that ultimately produced the drug.
- 3) *Elvitegravir*
Hisashi Shinkai described the discovery of elvitegravir, a new HIV-1 integrase inhibitor by using a 4-quinolone-3-carboxylic acid scaffold. The once-daily single tablet of a combination of elvitegravir with a CYP3A4 inhibitor and a nucleoside reverse transcriptase inhibitor afforded potent and durable antiretroviral efficacy.
- 4) *Linagliptin*
Matthias Eckhardt, Thomas Klein, Herbert Nar, and Sandra Thiemann have written about the discovery of linagliptin a highly potent and long-acting DPP-4 inhibitor. Linagliptin has a non-linear pharmacokinetic and nonrenal elimination profile, unique within the class of approved DPP-4 inhibitors.
- 5) *Pemetrexed*
Edward C. Taylor gives an overview on the discovery of pemetrexed representing an excellent long term collaboration between academia and industry. The individual interest of the author in pterine chemistry provided a starting point for the discovery of pemetrexed, which is used for the treatment of pleural mesothelioma and non-small cell lung cancer.
- 6) *Perampanel*
Shigeki Hibi described the discovery of perampanel, a novel, noncompetitive AMPA receptor antagonist for the treatment of epilepsy. Starting from HTS, optimization of a promising triaryl-1*H*-pyridin-2-one scaffold afforded perampanel, which is the first AMPA antagonist approved as an antiepileptic drug.
- 7) *Telaprevir*
B. Govinda Rao, Mark A. Murcko, Mark J. Tebbe, and Ann D. Kwong have written the chapter on the discovery of telaprevir, a protease inhibitor to treat hepatitis C infection. Telaprevir, a NS3/NS4A serine protease inhibitor, was successfully used between 2011 and 2013 in triple combination with ribavirin and interferon.
- 8) *Trastuzumab emtansine*
Sandhya Girish, Gail D. Lewis Phillips, Fredric S. Jacobson, Jagath R. Junutula, and Ellie Guardino described the discovery and development

of trastuzumab emtansine. The antibody drug conjugate represents a novel approach in treating patients with HER-2-positive cancer. The drug conjugate enables selective delivery of DM-1, a potent cytotoxic agent, into HER-2-positive target cells.

Last but not least the editors and authors thank the coworkers of Wiley-VCH, especially Dr. Frank Weinreich for the excellent cooperation.

June 2014
Budapest, Hungary
Montclair, NJ, USA

János Fischer
David P. Rotella

List of Contributors

John M. Beals

Lilly Research Laboratories
Lilly Corporate Center
Indianapolis, IN 46285
USA

Matthias Eckhardt

Boehringer Ingelheim Pharma
Division Research Germany
88397 Biberach an der Riss
Germany

János Fischer

Gedeon Richter Plc.
Department of Medicinal
Chemistry
Gyömrői út 30
1103 Budapest
Hungary

Sandhya Girish

Genentech
1 DNA Way
South San Francisco, CA 94080
USA

Ellie Guardino

Genentech
1 DNA Way
South San Francisco, CA 94080
USA

Shigeki Hibi

Eisai Product Creation Systems
Strategic Operations
Koishikawa 4-6-10
Bunkyo-ku
Tokyo 112-8088
Japan

Fredric S. Jacobson

Genentech
1 DNA Way
South San Francisco, CA 94080
USA

Jagath R. Junutula

Genentech
1 DNA Way
South San Francisco, CA 94080
USA

and

Cellerant Therapeutics
1561 Industrial Rd
San Carlos, CA 94070
USA

Kohei Kikkawa

Mitsubishi-Tanabe
Pharmacology Research
Laboratories II
2-2-50 Kawagishi
Toda 335-8505
Japan

Thomas Klein

Boehringer Ingelheim Pharma
Division Research Germany
88397 Biberach an der Riss
Germany

Ann D. Kwong

InnovaTID
125 CambridgePark Drive
Suite 301
Cambridge, MA 02140
USA

Gail D. Lewis Phillips

Genentech
1 DNA Way
South San Francisco, CA 94080
USA

Mark Murcko

Department of Biochemical
Engineering
MIT & Disruptive Biomedical,
LLC
520 Marshall Street
Holliston, MA 01746
USA

Herbert Nar

Boehringer Ingelheim Pharma
Division Research Germany
88397 Biberach an der Riss
Germany

Kenji Omori

Nagoya University
Graduate School of
Pharmaceutical Sciences
Furo-cho
Chikusa-ku
Nagoya 464-8601
Japan

Bhisetti G. Rao

Drug Design Expert LLC
19 Minute Man Ln
Lexington, MA 02421
USA

David P. Rotella

Montclair State University
Department of Chemistry &
Biochemistry
Montclair, NJ 07043
USA

Toshiaki Sakamoto

Mitsubishi-Tanabe
Medicinal Chemistry Research
Laboratories II
2-2-50 Kawagishi
Toda 335-8505
Japan

Hisashi Shinkai

JT Inc.
Central Pharmaceutical Research
Institute
1-1 Murasaki-cho
Takatsuki
Osaka 569-1125
Japan

David C. Swinney

Institute for Rare and Neglected
Diseases Drug Research
897 Independence Avenue
Suite 2C
Mountain View, CA 94043
USA

Edward C. Taylor

Princeton University
Department of Chemistry
Princeton, NJ 08544
USA

and

288 Western Way
Princeton, NJ 08540
USA

Mark J. Tebbe

Tebbe Consulting, LLC
282 Renfrew Street
Arlington, MA 02476
USA

Sandra Thiemann

Boehringer Ingelheim Pharma
Corporate Division Medicine
55216 Ingelheim am Rhein
Germany

William N. Washburn

(retired from
Bristol-Myers-Squibb)
120 Pleasant Valley Rd
Titusville
NJ 08560-1909
USA

Koichiro Yamada

Mitsubishi-Tanabe
Medicinal Chemistry Research
Laboratories II
2-2-50 Kawagishi
Toda 335-8505
Japan

Contents

Preface *XIII*

List of Contributors *XVII*

Part I General Aspects 1

1	Serendipitous Target-Based Drug Discoveries 3
	<i>János Fischer and David P. Rotella</i>
1.1	Introduction 3
1.2	Recent Examples of Target-Based Drug Discovery 4
1.3	Serendipitous Target-Based Drug Discoveries 7
1.4	Drospirenone (Contraceptive with Anti-aldosterone Activity) 7
1.4.1	Summary of Drospirenone Discovery 8
1.5	Escitalopram (Selective Serotonin Reuptake Inhibitor Antidepressant) 9
1.5.1	Summary of the Escitalopram Discovery 11
1.6	Ezetimibe (Inhibitor of Cholesterol Absorption) 11
1.6.1	Summary of Ezetimibe Discovery 13
1.7	Lamotrigine (Discovery of a Standalone Drug for the Treatment of Epilepsy) 13
1.7.1	Summary of Lamotrigine Discovery 15
1.8	Omeprazole (Proton Pump Inhibitor Acid-Suppressive Agent) 15
1.8.1	Summary of Omeprazole Discovery 16
1.9	Outlook 17
	Acknowledgments 17
	List of Abbreviations 17
	References 18
2	Drug Discoveries and Molecular Mechanism of Action 19
	<i>David C. Swinney</i>
2.1	Introduction 19
2.2	Mechanistic Paradox 19
2.3	Molecular Mechanism of Action 20

2.3.1	The Primary Driver of an Optimal MMOA is the Potential for Mechanism-Based Toxicity	22
2.3.2	Details of MMOA are not Captured by IC_{50} and K_I	22
2.3.3	Metrics, Biochemical Efficiency	24
2.4	How MMOAs were Discovered	25
2.4.1	MMOAs of Medicines Approved by the USFDA Between 1999 and 2008	27
2.5	Case Study: Artemisinin	30
2.6	Summary	31
	List of Abbreviations	32
	References	32

Part II Drug Class 35

3	Insulin Analogs – Improving the Therapy of Diabetes	37
	<i>John M. Beals</i>	
3.1	Introduction	37
3.2	Pharmacology and Insulin Analogs	38
3.3	Chemical Description	39
3.4	Rapid-Acting Insulin Analogs (Prandial or Bolus Insulin)	41
3.5	Long-Acting Insulin Analog Formulations (Basal Insulin)	48
3.6	Conclusions and Future Considerations	54
	List of Abbreviations	55
	References	55

Part III Case Histories 61

4	The Discovery of Stendra™ (Avanafil) for the Treatment of Erectile Dysfunction	63
	<i>Koichiro Yamada, Toshiaki Sakamoto, Kenji Omori, and Kohei Kikkawa</i>	
4.1	Introduction	63
4.2	Discovery of Avanafil	65
4.2.1	Differentiation Strategies to Develop a New Drug	65
4.2.2	Discovery of Isoquinoline Derivatives from Isoquinolinone Lead	65
4.2.3	Scaffold-Hopping Approaches from the Isoquinoline Leads	67
4.2.3.1	Monocyclic Type A Series: Tetrasubstituted Pyrimidine Derivatives	68
4.2.3.2	Monocyclic Type B Series: Trisubstituted Pyrimidine Derivatives	68
4.2.3.3	SAR of Substitution at the 2-Position of the Pyrimidine Ring (15)	70
4.2.3.4	SAR of Substitution at the 4-Position of the Pyrimidine Ring (16)	70
4.2.3.5	SAR of Substitution at the 5-Position of the Pyrimidine Ring (19, 20)	73
4.2.3.6	Core Structure Modifications of the Pyrimidine Nucleus of Avanafil	73